• Home
  • FDA Preclinical Safety Evaluation of Biotechnology Derived Pharmaceuticals (2009)

FDA S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology – Derived Pharmaceuticals (2009)

We are committed to provide our sponsors with high-quality bioanalytical services and support. Please contact us for any
COVID-19 related questions.